Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index falling 2.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.3%.
The iShares Biotechnology ETF (IBB) shed 0.7%.
In corporate news, NeOnc Technologies (NTHI) said the US Food and Drug Administration rescheduled its end-of-phase 1 type B meeting for oral cancer drug NEO212 to Monday from Nov. 17. The meeting's scheduling "does not establish FDA agreement on a trial design or eventual approval of NEO212," the company said Thursday in a statement. Its shares fell 20%.